Exhibit 10.10
 *Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
 THIRD AMENDMENT TO  EXCLUSIVE DISTRIBUTION AGREEMENT  BETWEEN  AKORN, INC., AND  MASSACHUSETTS BIOLOGICAL LABORATORIES
 Third Amendment Effective Date MBL Akorn Party Parties
 Recitals
 WHEREAS Exclusive Distribution
Agreement Agreement
 WHEREAS First Amendment Second Amendment Modified
Exclusive Distribution Agreement Modified Agreement
 WHEREAS
 NOW, THEREFORE
 Amendment
 1.
    
    Consideration. The Parties agree that the consideration for this Third
Amendment consists of the mutual benefits arising from the modifications
set out below.2.
    
    Amendment to Section2(a)(1)(2). Section 2(a)(1)(2) is hereby corrected
by deleting the Section in its entirety and replacing it with the following
language:
 2(a)(1)(2)
    
    Delivery of Single Dose Vials to Akorn. MBL will make
available to Akorn for pickup [***...***]doses in single dose
vials (the Replacement Doses) in consideration of Akorns
timely payment of the first installment of the Year 1
Resolution Amount (as such term is defined in Section
2 (a)(3) (Akorn Resolution Payment) below). Of the
  1




---



##### 



*Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
 [***...***] [***...***] [***...***]
 3.
    
    Confidentiality. The Parties understand and agree that the terms and conditions of this Third Amendment are and shall at all times
remain confidential. Neither Party shall disclose the terms or conditions of this Amendment, except for required disclosures to: (a) tax advisors;
(b) attorneys; (c) accountants; or (d) if required to do so by law, regulatory authorities, or legal process.4.
    
    Effect of Amendment. Nothing in this Third Amendment is intended to
modify, alter, reduce or change the rights or obligations of Akorn
and MBL in the Modified Exclusive Distribution Agreement, except as
expressly
stated in this Third Amendment. In the event there is any
conflict between the terms of this Third Amendment and the terms
of the Modified Agreement, the terms of this Third Amendment shall
control.5.
    
    Continued Effectiveness. Unless specifically modified or amended by
the terms of this Third Amendment, all the terms, conditions,
liabilities and obligations of the Modified Exclusive Distribution Agreement shall
be and remain applicable, in effect, valid, and enforceable between
the parties and applicable to this Third Amendment; all in
accordance with the terms of the Modified Exclusive Distribution
Agreement.6.
    
    Additional Defined Terms. Capitalized terms used herein and not
otherwise defined shall have the meaning ascribed to such terms
in the Modified Exclusive Distribution Agreement.7.
    
    Execution in Counterparts. This Third Amendment may be
executed in one or more counterparts, each of which when so executed will be
deemed to be an original, and all such counterparts together will constitute but one and the same instrument.In Witness Whereof, the Parties have caused this Amendment to
be executed by their duly authorized representatives.
  2




---



##### 



*Confidential Treatment Requested Under
17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
 Akorn, Inc.
    
    Massachusetts BiologicLaboratories of the University ofMassachusetts Medical SchoolBy:
    
    /s/ Arthur Przybyl
    
    By:
    
    /s/ Donna M. Ambrosino, M.D.Arthur Przybyl
    
    
    
    Donna M. Ambrosino, M.D.President and CEO
    
    
    
    Director
  3